<a href="https://laohu8.com/S/MRNA">Moderna</a>, Merck's skin cancer vaccine shows sustained benefit after five yearsJan 20 (Reuters) - Moderna MRNA.O and Merck MRK.N said on Tuesday their experimental vaccine for a serious type of skin cancer, used in combination with Keytruda, reduced the risk of recurrence or death by 49% in a mid-stage trial.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments